Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

Nexium Control given stamp of approval from consumers

Pfizer’s heartburn medication Nexium Control has been voted General Healthcare Product of the Year in an independent survey.

Product of the Year is the UK’s largest independent survey into product innovation, with more than 11,500 consumers taking part.

The initiative’s CEO Mike Nolan said he was delighted to give the proton pump inhibitor, which was reclassified as an over-the-counter (OTC) item in February 2015, his organisation’s “trusted stamp of approval”.

Nexium Control senior medical manager Kristie Sourial said greater accessibility to OTC medicines helps reduce pressure on the NHS, by allowing people to self-manage conditions.

Nexium Control works by blocking acid production in the stomach and is designed to provide up to 24 hours of protection against heartburn with one tablet a day.

A pack of seven tablets retails for £6.99, while a pack of 14 is £11.99.

To order, contact 0333 555 2526

Topics

         
Pharmacist Manager
Barnsley
£30 per hour

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD008173

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel